The results ended up complex by uneven distribution of ApoE4 carriers among placebo and procedure groups, which was because of an EMA request in the course of the demo. A subgroup Evaluation, introduced at CTAD, suggested the procedure benefit was not as a result of this imbalance (Nov 2018 meeting https://buytofidencetocilizumab-b56677.blog-eye.com/27853913/manual-article-review-is-required-for-this-article